Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 121 Neoplasm Metastasis 12 Prostate Cancer Metastatic 4 Oligometastatic Prostate Cancer 3 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 3 Metastatic Hormone-sensitive Prostate Cancer 3 Adenocarcinoma 3 Radiation Injuries 2 Prostatic Diseases 2 Prostate CA 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms 2 Metastatic Castration-resistant Prostate Cancer 2 Urologic Diseases 1 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Stage IV Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Salivary Gland Neoplasms 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Adenocarcinoma 1 PSA Level Greater Than 0.03 1 Oligorecurrent and Oligoprogressive Prostate Cancer Patients 1 Non-metastatic, Hormone naïve Prostate Cancer 1 Neoplasm Recurrence, Local 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Hormone-Sensitive Prostate Cance 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castration-sensitive Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 5 Radiosurgery 4 luprolide acetate gel depot 3 enzalutamide 3 Radiotherapy 3 Radiation 3 Leuprolide 3 Goserelin 3 relugolix 2 gallium 68 PSMA-11 2 bicalutamide 2 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2 Triptorelin Pamoate 2 Specimen Handling 2 Proton Therapy 2 Biopsy 2 radium Ra 223 dichloride 1 niraparib 1 histrelin 1 fluciclovine F-18 1 flibanserin 1 entinostat 1 darolutamide 1 atezolizumab 1 apalutamide 1 abiraterone 1 X-Rays 1 Watchful Waiting 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Adenocarcinoma × Androgen Antagonists × Clear all

NCT04743934 2025-05-04

RAD 2003

University of Alabama at Birmingham

Phase 2 Active not recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡